The FDA has approved the first PROTAC in any indication, supported by phase 3 VERITAC-2 data.
May 2026 Brief
The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.
The FDA has authorized expanded access to the RAS inhibitor daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.
A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.